Our proprietary mAb destroys senescent cells which are causally implicated in cancers and other diseases in which senescent cells secrete factors that exacerbate inflammation. The mAb has been humanized and our first indication will be osteoarthritis. In August 2017 we requested guidance for the FDA on sufficiency of our research plan leading to filing of an IND in about 16 months.